Acadia Pharma (ACAD) Misses Q4 EPS by 7c
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $16.59 --0%
Revenue Growth %: +76.2%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
UXIN, TOWN, NRIM, More
Revenue Growth %: +76.2%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
UXIN, TOWN, NRIM, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q4 EPS of ($0.45), $0.07 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $17 thousand versus the consensus estimate of $60 thousand.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- STMicroelectronics N.V. (STM) Misses Q1 EPS by 9c; offers Q2 outlook
- ESSA Bancorp (ESSA) Tops Q2 EPS by 13c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
